Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

TECX stock reached a new 52-week high this week, with shares trading at an impressive $53.6. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...